A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups

Kikuchi, Takashi; Gittins, John
August 2011
Statistical Methods in Medical Research;Aug2011, Vol. 20 Issue 4, p389
Academic Journal
The behavioural Bayes approach to sample size determination for clinical trials assumes that the number of subsequent patients switching to a new drug from the current drug depends on the strength of the evidence for efficacy and safety that was observed in the clinical trials. The optimal sample size is the one which maximises the expected net benefit of the trial. The approach has been developed in a series of papers by Pezeshk and the present authors (Gittins JC, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34: 355—63; Gittins JC, Pezeshk H. How Large should a clinical trial be? The Statistician 2000; 49(2): 177—87; Gittins JC, Pezeshk H. A decision theoretic approach to sample size determination in clinical trials. Journal of Biopharmaceutical Statistics 2002; 12(4): 535—51; Gittins JC, Pezeshk H. A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses. Drug Information Journal 2002; 36: 143—50; Kikuchi T, Pezeshk H, Gittins J. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Statistics in Medicine 2008; 27(1): 68—82; Kikuchi T, Gittins J. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety. Statistics in Medicine 2009; 28(18): 2293—306; Kikuchi T, Gittins J. A Bayesian procedure for cost-benefit evaluation of a new drug in multi-national clinical trials. Statistics in Medicine 2009 (Submitted)). The purpose of this article is to provide a rationale for experimental designs which allocate more patients to the new treatment than to the control group. The model uses a logistic weight function, including an interaction term linking efficacy and safety, which determines the number of patients choosing the new drug, and hence the resulting benefit. A Monte Carlo simulation is employed for the calculation. Having a larger group of patients on the new drug in general makes it easier to recruit patients to the trial and may also be ethically desirable. Our results show that this can be done with very little if any reduction in expected net benefit.


Related Articles

  • Markov chain sampling and the product estimator. Fishman, George S. // Operations Research;Nov/Dec94, Vol. 42 Issue 6, p1137 

    Several recent papers have suggested using a product estimator in Monte Carlo Markov chain sampling for estimating the volume of a convex body, the permanent of a matrix and the distribution of first-passage time for a positive recurrent Markov chain. The present paper analyzes the properties of...

  • APPLICATION OF STATISTICAL CRITERIA TO OPTIMALITY TESTING IN STOCHASTIC PROGRAMMING. Sakalauskas, Leonidas; Žilinskas, Kestutis // Technological & Economic Development of Economy;2006, Vol. 12 Issue 4, p314 

    In this paper the stochastic adaptive method has been developed to solve stochastic linear problems by a finite sequence of Monte-Carlo sampling estimators. The method is grounded on adaptive regulation of the size of Monte-Carlo samples and the statistical termination procedure, taking into...

  • Latin hypercube sampling for uncertainty analysis in multiphase modelling. Khan, Amir Ali; Lye, Leonard; Husain, Tahir // Journal of Environmental Engineering & Science;Nov2008, Vol. 7 Issue 6, p617 

    To facilitate the uncertainty analysis of a finite element multiphase multi-component transport model MOFAT, this paper provides guidance on latin hypercube sampling Monte Carlo (LHS-MC) sample size selection. To evaluate the ability of LHS-MC to produce output cumulative distribution functions...

  • Short Notes: Averaging Correlation Coefficients: Should Fisher's z Transformation Be Used? Silver, N. Clayton; Dunlap, William P. // Journal of Applied Psychology;Feb87, Vol. 72 Issue 1, p146 

    Averaging correlations leads to underestimation because the sampling distribution of the correlation coefficient is skewed. It is also known that if correlations are transformed by Fisher's z prior to averaging, the resulting average overestimates the population value of z. The behavior of these...

  • Biases and Standard Errors of Standardized Regression Coefficients. Yuan, Ke-Hai; Chan, Wai // Psychometrika;Dec2011, Vol. 76 Issue 4, p670 

    The paper obtains consistent standard errors (SE) and biases of order O(1/ n) for the sample standardized regression coefficients with both random and given predictors. Analytical results indicate that the formulas for SEs given in popular text books are consistent only when the population value...

  • Parameter Estimation for Type III Discrete Weibull Distribution: A Comparative Study. Barbiero, Alessandro // Journal of Probability & Statistics;2013, p1 

    The type III discrete Weibull distribution can be used in reliability analysis for modeling failure data such as the number of shocks, cycles, or runs a component or a structure can overcome before failing. This paper describes three methods for estimating its parameters: two customary...

  • Evaluation of the Propensity score methods for estimating marginal odds ratios in case of small sample size. Pirracchio, Romain; Resche-Rigon, Matthieu; Chevret, Chevret // BMC Medical Research Methodology;2012, Vol. 12 Issue 1, p70 

    Background: Propensity score (PS) methods are increasingly used, even when sample sizes are small or treatments are seldom used. However, the relative performance of the two mainly recommended PS methods, namely PS-matching or inverse probability of treatment weighting (IPTW), have not been...

  • Using the Bernoulli trial approaches for detecting ordered alternatives. Chia-Hao Chang; Chih-Chien Chin; Weichieh Wayne Yu; Ying-Yu Huang // BMC Medical Research Methodology;2013, Vol. 13 Issue 1, p1 

    Background Diagnostic problems in clinical trials are sometimes ordinal. For example, colon tumor staging was performed according to the TNM classification. However, clinical data are limited by markedly small sample sizes in some stage. Methods We propose a distribution-free test for detecting...

  • Adjusting batch effects in microarray expression data using empirical Bayes methods. Cheng Li // Biostatistics;Jan2007, Vol. 8 Issue 1, p118 

    Non-biological experimental variation or “batch effects" are commonly observed across multiple batches of microarray experiments, often rendering the task of combining data from these batches difficult. The ability to combine microarray data sets is advantageous to researchers to increase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics